combating fatigue on semaglutide The EASIEST Way to Get Rid of Side Effects A case report of semaglutide

Aust N Z J Obstet Gynaecol 1999;39:99102

Anderson Cancer Center commenced a dose-finding and safety study into adipotide in 2012, the human trial was discontinued for unspecified reasons and no safety data was made publicly available [2]

Current evidence shows: Research is ongoing to determine how newer oral formulations will compare long-term

Studies confirm our smell can be affected by GLP-1 agonists leading to increased and decreased sensitivity, reports one research body

Patients should be counselled that optimising blood glucose levels remains the cornerstone of reducing infection risk, and any new or recurrent symptoms warrant clinical assessment rather than self-diagnosis or treatment cessation

Meneguzzi A, Fava C, Castelli M, et al